We’re tracking in-house compensation. Take the Law360 Survey
Click here
Merck Sharp & Dohme LLC v. The Johns Hopkins University
-
November 18, 2025
The Patent Trial and Appeal Board invalidated a cancer treatment patent owned by Johns Hopkins University, marking a full victory on the nine challenges Merck Sharp & Dohme LLC initiated against the university's patents.
-
November 07, 2025
Another cancer treatment patent owned by Johns Hopkins University and challenged by a Merck & Co. Inc. subsidiary didn't pass muster with the Patent Trial and Appeal Board, which on Thursday invalidated seven claims in the patent that's at issue in a disagreement between the parties.
-
September 19, 2025
The Patent Trial and Appeal Board has invalidated an anti-cancer therapy patent owned by Johns Hopkins University, handing a win to challenger Merck Sharp & Dohme LLC in a larger fight relating to Merck's Keytruda treatment.
-
June 10, 2025
Merck & Co. Inc. subsidiary Merck Sharp & Dohme LLC has notched a win at the Patent Trial and Appeal Board in its disagreement with Johns Hopkins University over a cancer research partnership, persuading a panel to invalidate claims in a university-owned patent relating to a colorectal cancer treatment.
-
November 29, 2022
Merck Sharp took Johns Hopkins University to federal court in Maryland on Tuesday over claims that the university secretly obtained patents for inventions based on a collaborative clinical study treating cancer patients with Merck Sharp's Keytruda drug and funding, and then licensing the patents to others in violation of their contract.